Human tumor assay coverage
This article was originally published in The Gray Sheet
Laboratory and Diagnostic Services Panel of MCAC convenes Nov. 15 from 8 a.m. to 4 p.m. and Nov. 16 from 8 a.m. to 12 noon in Baltimore to discuss human tumor assays, such as Oncotech's extreme drug resistance test, which previously has been the subject of an admininstrative law judge appeal (1"The Gray Sheet" July 26, p. 12)
You may also be interested in...
Legislation designed to accelerate the process for appealing Medicare coverage decisions by the Health Care Financing Administration and its intermediaries could cost as much as $1-2 bil. over five years, according to Rep. Bill Thomas (R-Calif.), sponsor of the legislation and chairman of the House Ways and Means/Health Subcommittee.
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.